Reference:
FLCCC Alliance. (2023). I-CARE early COVID treatment summary. Retrieved from https://www.flccc.net
Summary:
The FLCCC Alliance outlines a structured protocol for the early treatment of COVID-19, emphasising the importance of immediate intervention after the onset of symptoms. First-line treatments include Ivermectin (0.4-0.6 mg/kg), Hydroxychloroquine (200 mg twice daily), and antiseptic mouthwash for symptom management. Ivermectin should be taken with meals for optimal absorption, and care is advised when combining it with quercetin due to potential interactions. The protocol also includes nutritional support through vitamins and supplements such as zinc, Vitamin C, and melatonin, advocating for their use in pregnant women when appropriate. It stresses the significance of treating COVID-19 early to prevent severe disease progression and hospitalisation, noting that while PCR testing is not necessary, monitoring symptoms closely is crucial. Furthermore, the document provides guidance on additional therapies and potential drug interactions. The FLCCC aims to update these protocols continually based on emerging evidence, promoting optimal care for patients worldwide. This structured approach serves as a guide for healthcare professionals, ensuring that early treatment is prioritised in managing COVID-19 effectively.